Search companies

Live

CLEVER CULTURE SYSTEMS LIMITED (ASX: CC5)

Health care · News and insights

CC5: $0.016 +14.29% · MC: $36M

Latest CC5 announcements

Announcement Insights

Clever Culture Systems Reaffirms FY27 Sales Outlook As Smaller APAS Model Advances

Clever Culture Systems has completed six of the eight APAS instrument sales and new evaluations it expects in the first half of FY27, matching its full-year FY26 pharmaceutical placements; two more are expected by year-end, including an order from a new top-20 pharmaceutical company. The company secured a $2.6 million funding package to develop APAS Revolution for smaller facilities, with customer evaluations targeted for 2027 and launch expected in the first half of 2028.

Updated 17 Nov 2026, 11:44 AM Sydney time
Share
SourcesChair's Address to ShareholdersAGM Managing Director's PresentationApplication for quotation of securities - CC5Notification regarding unquoted securities - CC5Funding Raised for Development of a New Benchtop InstrumentProposed issue of securities - CC5Quarterly Activities/Appendix 4C Cash Flow ReportTrading HaltChange of Registry Address NotificationAdvancing Sales Pipeline Underpins Growth Momentum
Comments

Clever Culture Systems Reaffirms FY27 Sales Outlook As Pharma Orders Build

2026-11-17 · Health care

CC5: $0.016 +14.29% · MC: $36M

Clever Culture Systems says first-half FY27 sales and new evaluations are expected to reach eight APAS instruments, matching its full-year FY26 pharmaceutical placements; six are completed, with two more expected by year-end, including an order from a new top-20 pharmaceutical company. The company also reiterated plans for APAS Revolution, targeting a market it estimates is around 50% larger, with customer evaluations expected in 2027 and launch in the first half of 2028.

Updated 2026-11-17 11:39
Share
SourcesAGM Managing Director's PresentationChair's Address to Shareholders
Comments

Clever Culture Systems Issues Shares And Options Under Previously Announced Funding

2026-11-10 · Health care

CC5: $0.015 -11.76% · MC: $36M

Clever Culture Systems issued new shares and options under the funding package announced last week to support development of its smaller APAS system. The share issue increases its quoted ordinary shares, while the options are unquoted and 28.8 million further options under the package remain to be issued.

Updated 2026-11-10 10:35
Share
SourcesApplication for quotation of securities - CC5Notification regarding unquoted securities - CC5
Comments

Clever Culture Systems Raises $2.6 Million to Develop Smaller APAS System, Expanding Target Market

2026-11-03 · Health care

CC5: $0.016 -15.79% · MC: $36M

Clever Culture Systems has secured commitments for a $2.6 million funding package—comprising a targeted share placement and an unsecured loan—to develop APAS Revolution, a smaller system aimed at pharmaceutical facilities not served by its existing product. The company estimates the product could expand APAS’s addressable market by approximately 50%, from $2.8 billion to $4.3 billion, while the proposed launch is expected in the first half of 2028. This follows last week’s update that three APAS Independence systems were sold and invoiced in the first quarter of FY27, with eight sales and new evaluations expected in the first half.

Updated 2026-11-03 10:22
Share
SourcesFunding Raised for Development of a New Benchtop InstrumentProposed issue of securities - CC5
Comments

Clever Culture Systems Seeks Capital Raise After Three APAS Sales

2026-10-30 · Health care

CC5: $0.019 +0.00% · MC: $36M

Clever Culture Systems reported three completed and invoiced APAS sales in Q1 FY27, up from one in the same quarter last year, and expects first-half sales and new evaluations to reach eight units, matching full-year FY26 sales to pharmaceutical customers. Separately, it requested a trading halt while completing a material capital raise intended to fund development of a smaller desktop APAS model for lower-volume sterile drug manufacturing facilities.

Updated 2026-10-30 09:12
Share
SourcesQuarterly Activities/Appendix 4C Cash Flow ReportTrading Halt
Comments

Clever Culture Systems reports three completed sales as expected first-half pipeline reaches eight units

2026-10-28 · Health care

CC5: $0.019 +2.70% · MC: $36M

Clever Culture Systems says three APAS Independence sales were completed and fully invoiced in the first quarter of FY27, while it expects first-half sales and new evaluations to reach eight units, matching the full-year FY26 total sold to pharmaceutical customers. Two existing global pharmaceutical customers are expected to progress to purchases, and a new top-20 pharmaceutical company is expected to begin a paid evaluation; these opportunities remain subject to conversion.

Updated 2026-10-28 08:37
Share
SourcesAdvancing Sales Pipeline Underpins Growth Momentum
Comments